论文部分内容阅读
目的 观察莫沙比利联合抗幽门螺杆菌(HP)三联方案治疗反流性食管炎的疗效。方法对2组HP感染阳性的反流性食管炎患者采用莫沙比利加PPI(质子泵抑制剂)三联及铋剂三联的两种方法治疗,观察其临床症状、内镜下愈合及胃内HP感染阴转的情况。结果 PPI组临床症状4周缓解率为81.4％(22/27),内镜下愈合及好转率为88.8％(24/27);铋剂组为69.2％(27/39)和81.0％(30/39)。HP转阴率2组用药4周后分别为72.2％和84％。PPI组在快速消除症状上明显优于铋剂组,但HP转阴率两组无明显差异。结论 莫沙比利联合PPI方案治疗反流性食管炎在临床上近期有明显疗效,并具有抗HP感染的作用,远期疗效尚待进一步观察。
Objective To observe the efficacy of mosapride combined with anti-helicobacter pylori (HP) triple regimen in the treatment of reflux esophagitis. Methods Two groups of HP infection-positive patients with reflux esophagitis were treated with mosapride plus PPI (proton pump inhibitor) triple therapy and bismuth triple therapy. The clinical symptoms, endoscopic healing and intragastric HP Negative infections. Results The 4-week remission rate of clinical symptom in PPI group was 81.4% (22/27), the rate of healing and improvement was 88.8% (24/27) in endoscopic group and 69.2% (27/39) and 81.0% (30%) in bismuth group / 39). HP negative rate of two groups were 72.2% and 84% after 4 weeks of treatment. PPI group in the rapid elimination of symptoms was significantly better than the bismuth group, but the HP negative conversion rate was no significant difference between the two groups. Conclusion Mosapride combined with PPI regimen in the treatment of reflux esophagitis in the recent clinical significant effect, and has anti-HP infection, long-term efficacy remains to be further observed.